Found 5 results
Filters: Author is X.L. Ma  [Clear All Filters]
W. W. Zhu, Ma, X. L., Guo, A. L., Zhao, H. Y., and Luo, H. H., Neuroprotective effects of NEP1-40 and fasudil on Nogo-A expression in neonatal rats with hypoxic-ischemic brain damage, vol. 10, pp. 2987-2995, 2011.
Bertrand J, Winton MJ, Rodriguez-Hernandez N, Campenot RB, et al. (2005). Application of rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J. Neurosci. 25: 1113-1121. PMid:15689547 Cao Y, Shumsky JS, Sabol MA, Kushner RA, et al. (2008). Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat. Neurorehabil. Neural Repair 22: 262-278. PMid:18056009    PMCid:2853251 Fournier AE, Takizawa BT and Strittmatter SM (2003). Rho kinase inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 23: 1416-1423. PMid:12598630 Gillani RL, Tsai SY, Wallace DG, O’Brien TE, et al. (2010). Cognitive recovery in the aged rat after stroke and anti- Nogo-A immunotherapy. Behav. Brain Res. 208: 415-424. PMid:20035795    PMCid:2831114 Goldshmit Y, Galea MP, Wise G, Bartlett PF, et al. (2004). Axonal regeneration and lack of astrocytic gliosis in EphA4- deficient mice. J. Neurosci. 24: 10064-10073. PMid:15537875 GrandPre T, Li S and Strittmatter SM (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417: 547-551. PMid:12037567 Guo AL, Zhu WW, Wang L and Pan F (2008). Effect of NEP1-40 in inhibiting neurite outgrowth on neonatal rats with hypoxic ischemic brain damage. Chin. J. Child Health Care 16: 679-668. Hossain MA (2008). Hypoxic-ischemic injury in neonatal brain: involvement of a novel neuronal molecule in neuronal cell death and potential target for neuroprotection. Int. J. Dev. Neurosci. 26: 93-101. PMid:17936538    PMCid:2350216 Kim SS, Lee KH, Sung DK, Shim JW, et al. (2008). Erythropoietin attenuates brain injury, subventricular zone expansion, and sensorimotor deficits in hypoxic-ischemic neonatal rats. J. Korean Med. Sci. 23: 484-491. PMid:18583887    PMCid:2526527 Kottis V, Thibault P, Mikol D, Xiao ZC, et al. (2002). Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. J. Neurochem. 82: 1566-1569. PMid:12354307 Kubo T and Yamashita T (2007). Rho-ROCK inhibitors for the treatment of CNS injury. Recent Patents CNS Drug Discov. 2: 173-179. PMid:18221230 McKerracher L, David S, Jackson DL, Kottis V, et al. (1994). Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13: 805-811. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, et al. (1994). A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13: 757-767. Oertle T, van der Haar ME, Bandtlow CE, Robeva A, et al. (2003). Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J. Neurosci. 23: 5393-5406. PMid:12843238 Perlman JM (2006). Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin. Ther. 28: 1353-1365. PMid:17062309 Prinjha R, Moore SE, Vinson M, Blake S, et al. (2000). Inhibitor of neurite outgrowth in humans. Nature 403: 383-384. PMid:10667780 Rice JE III, Vannucci RC and Brierley JB (1981). The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann. Neurol. 9: 131-141. PMid:7235629 Savio T and Schwab ME (1990). Lesioned corticospinal tract axons regenerate in myelin-free rat spinal cord. Proc. Natl. Acad. Sci. U. S. A. 87: 4130-4133. Schnaar RL and Lopez PH (2009). Myelin-associated glycoprotein and its axonal receptors. J. Neurosci. Res. 87: 3267- 3276. PMid:19156870    PMCid:2892843 Vicari RM, Chaitman B, Keefe D, Smith WB, et al. (2005). Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 46: 1803-1811. PMid:16286163 Walmsley AR and Mir AK (2007). Targeting the Nogo-A signalling pathway to promote recovery following acute CNS injury. Curr. Pharm. Des. 13: 2470-2484. PMid:17692015 Wang H, Yao Y, Jiang X, Chen D, et al. (2006). Expression of Nogo-A and NgR in the developing rat brain after hypoxia-ischemia. Brain Res. 1114: 212-220. Wong ST, Henley JR, Kanning KC, Huang KH, et al. (2002). A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat. Neurosci. 5: 1302-1308. PMid:12426574 Yesilirmak DC, Kumral A, Tugyan K, Cilaker S, et al. (2008). Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain Res. 1210: 56-62. PMid:18420181
L. P. Sun, Ma, X. L., Liu, H. X., Wang, Y. S., and Li, X. F., No association of polymorphisms in the suppressor of cytokine signaling (SOCS)-3 with rheumatoid arthritis in the Chinese Han population, vol. 9, pp. 1518-1524, 2010.
Alexander WS (2002). Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2: 410-416. PMid:12093007   Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324. PMid:3358796   Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, et al. (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581. PMid:15201414   Egan PJ, Lawlor KE, Alexander WS and Wicks IP (2003). Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Invest. 111: 915-924. PMid:12639998 PMCid:153765   Firestein GS and Zvaifler NJ (1997). Anticytokine therapy in rheumatoid arthritis. N. Engl. J. Med. 337: 195-197. PMid:9219708   Gatto L, Berlato C, Poli V, Tininini S, et al. (2004). Analysis of SOCS-3 promoter responses to interferon gamma. J. Biol. Chem. 279: 13746-13754. PMid:14742442   GMSTF (2005). Genomatix MatInspector Search for Transcription Factor Binding Sites. Available at []. Acessed December 10, 2009.   Gylvin T, Nolsoe R, Hansen T, Nielsen EM, et al. (2004). Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in type 1 diabetes and insulin sensitivity. Diabetologia 47: 1273-1277. PMid:15249995   Hölter K, Wermter AK, Scherag A, Siegfried W, et al. (2007). Analysis of sequence variations in the suppressor of cytokine signaling (SOCS)-3 gene in extremely obese children and adolescents. BMC Med. Genet. 8: 21. PMid:17445271 PMCid:1866222   Isomaki P, Alanara T, Isohanni P, Lagerstedt A, et al. (2007). The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46: 1538-1546. PMid:17726036   Jamshidi Y, Snieder H, Wang X, Spector TD, et al. (2006). Common polymorphisms in SOCS3 are not associated with body weight, insulin sensitivity or lipid profile in normal female twins. Diabetologia 49: 306-310. PMid:16402267 PMCid:1364534   Maini R, St Clair EW, Breedveld F, Furst D, et al. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.   Paul C, Seiliez I, Thissen JP and Le Cam A (2000). Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids mRNA analysis and promoter characterization. Eur. J. Biochem. 267: 5849-5857. PMid:10998044   Rahman A (2007). Regulators of cytokine signalling in rheumatoid arthritis. Rheumatology 46: 1745-1746. PMid:17986480   Rottapel R (2001). Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? J. Clin. Invest. 108: 1745-1747. PMid:11748257 PMCid:209478   Shi YY and He L (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15: 97-98. PMid:15740637   Shouda T, Yoshida T, Hanada T, Wakioka T, et al. (2001). Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108: 1781-1788. PMid:11748261 PMCid:209467   Smolen JS and Steiner G (2003). Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2: 473-488. PMid:12776222   Starr R, Willson TA, Viney EM, Murray LJ, et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921. PMid:9202125   Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, et al. (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259. PMid:9920948   Weinblatt ME, Keystone EC, Furst DE, Moreland LW, et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48: 35-45. PMid:12528101   Wong PK, Egan PJ, Croker BA, O'Donnell K, et al. (2006). SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest. 116: 1571-1581. PMid:16710471 PMCid:1462939